| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Jul 1, 2025 | Active | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Jul 1, 2025 | Active | N/A |
| Arsenic | Health-Based | N/A | 0.011 | Jun 30, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Total Haloacetic Acids (HAA5) | Health-Based | N/A | 0.0965 | Jun 30, 2025 | Resolved | N/A |
| TTHM | Health-Based | N/A | 0.14 | Jun 30, 2025 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.0141 | Jun 30, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.063 | Jun 30, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Total Haloacetic Acids (HAA5) | Health-Based | N/A | 0.14 | Jun 30, 2025 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Health-Based | N/A | 0.14 | Jun 30, 2025 | Resolved | N/A |
| TTHM | Health-Based | N/A | 0.1052 | Jun 30, 2025 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.012 | Mar 31, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| TTHM | Health-Based | N/A | 0.0962 | Mar 31, 2025 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Health-Based | N/A | 0.1425 | Mar 31, 2025 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.015 | Mar 31, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.059 | Mar 31, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Total Haloacetic Acids (HAA5) | Health-Based | N/A | 0.128 | Mar 31, 2025 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Health-Based | N/A | 0.128 | Mar 31, 2025 | Resolved | N/A |
| TTHM | Health-Based | N/A | 0.103 | Mar 31, 2025 | Resolved | N/A |
| TTHM | Health-Based | N/A | 0.103 | Mar 31, 2025 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.014 | Mar 31, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.018 | Mar 31, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jan 31, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jan 31, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jan 31, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jan 31, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jan 31, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jan 31, 2025 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.012 | Dec 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Total Haloacetic Acids (HAA5) | Health-Based | N/A | 0.0817 | Dec 31, 2024 | Resolved | N/A |
| TTHM | Health-Based | N/A | 0.1175 | Dec 31, 2024 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.034 | Dec 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Active | N/A |
| TTHM | Health-Based | N/A | 0.106 | Dec 31, 2024 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Health-Based | N/A | 0.134 | Dec 31, 2024 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Health-Based | N/A | 0.134 | Dec 31, 2024 | Resolved | N/A |
| TTHM | Health-Based | N/A | 0.106 | Dec 31, 2024 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.015 | Dec 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.015 | Dec 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Combined Uranium | Health-Based | N/A | 56.2 | Oct 30, 2024 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.0122 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| TTHM | Health-Based | N/A | 0.1125 | Sep 30, 2024 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Health-Based | N/A | 0.09875 | Sep 30, 2024 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 53 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Total Haloacetic Acids (HAA5) | Health-Based | N/A | 0.1078 | Sep 30, 2024 | Resolved | N/A |
| TTHM | Health-Based | N/A | 0.0835 | Sep 30, 2024 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.019 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| 1,2-DIBROMO-3-CHLOROPROPANE | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.0124 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Total Haloacetic Acids (HAA5) | Health-Based | N/A | 0.117 | Jun 30, 2024 | Resolved | N/A |
| TTHM | Health-Based | N/A | 0.132 | Jun 30, 2024 | Resolved | N/A |
| Arsenic | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Active | N/A |
| Total Haloacetic Acids (HAA5) | Health-Based | N/A | 0.102 | Jun 30, 2024 | Resolved | N/A |
| TTHM | Health-Based | N/A | 0.089 | Jun 30, 2024 | Resolved | N/A |
| TTHM | Health-Based | N/A | 0.089 | Jun 30, 2024 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Health-Based | N/A | 0.102 | Jun 30, 2024 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.0195 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Combined Uranium | Health-Based | N/A | 57.5 | Jun 30, 2024 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.013 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| TTHM | Health-Based | N/A | 0.123 | Mar 31, 2024 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Health-Based | N/A | 0.095 | Mar 31, 2024 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.017 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Total Haloacetic Acids (HAA5) | Health-Based | N/A | 0.102 | Mar 31, 2024 | Resolved | N/A |
| TTHM | Health-Based | N/A | 0.102 | Mar 31, 2024 | Resolved | N/A |
| Combined Uranium | Health-Based | N/A | 39.85 | Mar 31, 2024 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.017 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| 1,2-Dichloropropane | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| DICHLOROMETHANE | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| trans-1,2-Dichloroethylene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Vinyl chloride | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Increased risk of cancer |
| Vinyl chloride | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Increased risk of cancer |
| Tetrachloroethylene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Liver problems; increased risk of cancer |
| Tetrachloroethylene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Liver problems; increased risk of cancer |
| Benzene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Anemia; decrease in blood platelets; increased risk of cancer |
| Benzene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Anemia; decrease in blood platelets; increased risk of cancer |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Carbon tetrachloride | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Liver problems; increased risk of cancer |
| Carbon tetrachloride | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Liver problems; increased risk of cancer |
| Trichloroethylene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Liver problems; increased risk of cancer |
| Trichloroethylene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Liver problems; increased risk of cancer |
| Ethylbenzene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Ethylbenzene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| trans-1,2-Dichloroethylene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| 1,2-Dichloropropane | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Styrene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| 1,2,4-Trichlorobenzene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| 1,2,4-Trichlorobenzene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| cis-1,2-Dichloroethylene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| cis-1,2-Dichloroethylene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Xylenes, Total | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Xylenes, Total | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| o-Dichlorobenzene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| o-Dichlorobenzene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| p-Dichlorobenzene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| p-Dichlorobenzene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| 1,1-Dichloroethylene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| 1,1-Dichloroethylene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| 1,2-Dichloroethane | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| 1,2-Dichloroethane | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| 1,1,1-Trichloroethane | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| 1,1,1-Trichloroethane | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| 1,1,2-Trichloroethane | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| 1,1,2-Trichloroethane | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| CHLOROBENZENE | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| CHLOROBENZENE | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Toluene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Toluene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| DICHLOROMETHANE | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Styrene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.0125 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Total Haloacetic Acids (HAA5) | Health-Based | N/A | 0.13 | Dec 31, 2023 | Resolved | N/A |
| TTHM | Health-Based | N/A | 0.135 | Dec 31, 2023 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 40.8 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Total Haloacetic Acids (HAA5) | Health-Based | N/A | 0.115 | Dec 31, 2023 | Resolved | N/A |
| TTHM | Health-Based | N/A | 0.112 | Dec 31, 2023 | Resolved | N/A |
| Combined Uranium | Health-Based | N/A | 44 | Dec 31, 2023 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.02 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Arsenic | Health-Based | N/A | 0.01375 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| TTHM | Health-Based | N/A | 0.155 | Sep 30, 2023 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Health-Based | N/A | 0.111 | Sep 30, 2023 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.035875 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| TTHM | Health-Based | N/A | 0.121 | Sep 30, 2023 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Health-Based | N/A | 0.115 | Sep 30, 2023 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.02 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Combined Uranium | Health-Based | N/A | 44.5 | Sep 30, 2023 | Resolved | N/A |
| 1,2-DIBROMO-3-CHLOROPROPANE | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| 1,2-DIBROMO-3-CHLOROPROPANE | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.01425 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Total Haloacetic Acids (HAA5) | Health-Based | N/A | 0.109 | Jun 30, 2023 | Resolved | N/A |
| TTHM | Health-Based | N/A | 0.144 | Jun 30, 2023 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.0225 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Total Haloacetic Acids (HAA5) | Health-Based | N/A | 0.098 | Jun 30, 2023 | Resolved | N/A |
| TTHM | Health-Based | N/A | 0.113 | Jun 30, 2023 | Resolved | N/A |
| Surface Water Treatment Rule | Health-Based | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Surface Water Treatment Rule | Health-Based | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.02 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Combined Uranium | Health-Based | N/A | 44.5 | Jun 30, 2023 | Resolved | N/A |
| Surface Water Treatment Rule | Health-Based | N/A | N/A | May 31, 2023 | Resolved | N/A |
| Surface Water Treatment Rule | Health-Based | N/A | N/A | May 31, 2023 | Resolved | N/A |
| Surface Water Treatment Rule | Health-Based | N/A | N/A | Apr 30, 2023 | Resolved | N/A |
| Surface Water Treatment Rule | Health-Based | N/A | N/A | Apr 30, 2023 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.01425 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Surface Water Treatment Rule | Health-Based | N/A | N/A | Mar 31, 2023 | Resolved | N/A |
| TTHM | Health-Based | N/A | 0.149 | Mar 31, 2023 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Health-Based | N/A | 0.101 | Mar 31, 2023 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.02 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0206 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Combined Uranium | Health-Based | N/A | 40 | Mar 31, 2023 | Resolved | N/A |
| 1,2-DIBROMO-3-CHLOROPROPANE | Health-Based | N/A | 0.813 | Mar 31, 2023 | Resolved | N/A |
| 1,2-DIBROMO-3-CHLOROPROPANE | Health-Based | N/A | 0.813 | Mar 31, 2023 | Resolved | N/A |
| Surface Water Treatment Rule | Health-Based | N/A | N/A | Feb 28, 2023 | Resolved | N/A |
| Surface Water Treatment Rule | Health-Based | N/A | N/A | Feb 28, 2023 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.014 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Nitrate | Health-Based | N/A | 15 | Dec 31, 2022 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Health-Based | N/A | 15 | Dec 31, 2022 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| TTHM | Health-Based | N/A | 0.22 | Dec 31, 2022 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Health-Based | N/A | 0.15 | Dec 31, 2022 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.012 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Total Haloacetic Acids (HAA5) | Health-Based | N/A | 0.15 | Dec 31, 2022 | Resolved | N/A |
| TTHM | Health-Based | N/A | 0.13 | Dec 31, 2022 | Resolved | N/A |
| Combined Uranium | Health-Based | N/A | 42.5 | Dec 31, 2022 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.022 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| 1,2-DIBROMO-3-CHLOROPROPANE | Health-Based | N/A | 0.3115 | Dec 31, 2022 | Resolved | N/A |
| 1,2-DIBROMO-3-CHLOROPROPANE | Health-Based | N/A | 0.3115 | Dec 31, 2022 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Arsenic | Health-Based | N/A | 0.01375 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Total Haloacetic Acids (HAA5) | Health-Based | N/A | 0.093 | Sep 30, 2022 | Resolved | N/A |
| TTHM | Health-Based | N/A | 0.12 | Sep 30, 2022 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.014 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Total Haloacetic Acids (HAA5) | Health-Based | N/A | 0.0735 | Sep 30, 2022 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.0218 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0168 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| 1,2-DIBROMO-3-CHLOROPROPANE | Health-Based | N/A | 0.0003165 | Sep 30, 2022 | Resolved | N/A |
| 1,2-DIBROMO-3-CHLOROPROPANE | Health-Based | N/A | 0.0003165 | Sep 30, 2022 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2022 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.0135 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Total Haloacetic Acids (HAA5) | Health-Based | N/A | 93.3 | Jun 30, 2022 | Resolved | N/A |
| TTHM | Health-Based | N/A | 123 | Jun 30, 2022 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.0208 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.01203 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Total Haloacetic Acids (HAA5) | Health-Based | N/A | 74.5 | Jun 30, 2022 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.0182 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0163 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| 1,2-DIBROMO-3-CHLOROPROPANE | Health-Based | N/A | 0.49 | Jun 30, 2022 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.013 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| TTHM | Health-Based | N/A | 140 | Mar 31, 2022 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.01053 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0243 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Total Haloacetic Acids (HAA5) | Health-Based | N/A | 68.8 | Mar 31, 2022 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.0186 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0158 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| 1,2-DIBROMO-3-CHLOROPROPANE | Health-Based | N/A | 0.46 | Mar 31, 2022 | Resolved | N/A |
| 1,2-DIBROMO-3-CHLOROPROPANE | Health-Based | N/A | 0.46 | Mar 31, 2022 | Resolved | N/A |
| Antimony, Total | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Beryllium, Total | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Thallium, Total | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Thallium, Total | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Barium | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Increase in blood pressure |
| Barium | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Increase in blood pressure |
| Nickel | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Antimony, Total | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Selenium | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Hair or fingernail loss; numbness in fingers or toes; circulatory problems |
| Nitrite | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrite | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Fluoride | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Bone disease (pain and tenderness of the bones); children may get mottled teeth |
| Fluoride | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Bone disease (pain and tenderness of the bones); children may get mottled teeth |
| Chromium | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Allergic dermatitis |
| Nitrite | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrite | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Chromium | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Allergic dermatitis |
| Cadmium | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Kidney damage |
| Cadmium | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Kidney damage |
| Arsenic | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Selenium | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Hair or fingernail loss; numbness in fingers or toes; circulatory problems |
| Beryllium, Total | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Mercury | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Kidney damage |
| Mercury | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Kidney damage |
| Arsenic | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Nickel | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.0135 | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Arsenic | Health-Based | N/A | 0.01003 | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0295 | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Atrazine | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Cardiovascular system or reproductive problems |
| Simazine | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| LASSO | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.0187 | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0158 | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Combined Uranium | Health-Based | N/A | 44.25 | Dec 31, 2021 | Resolved | N/A |
| Total Polychlorinated Biphenyls (PCB) | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Toxaphene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Dalapon | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Diquat | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Di(2-ethylhexyl) adipate | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| OXAMYL | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Simazine | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Di(2-ethylhexyl) phthalate | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Picloram | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Dinoseb | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Hexachlorocyclopentadiene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| LASSO | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| 2,3,7,8-TCDD | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Heptachlor | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| 2,4,5-TP | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Benzo(a)pyrene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Pentachlorophenol | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| ETHYLENE DIBROMIDE | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Chlordane | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Nitrite | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Methoxychlor | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Heptachlor epoxide | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Glyphosate | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| 1,2-DIBROMO-3-CHLOROPROPANE | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Endothall | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| 2,4-D | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Endrin | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Atrazine | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Cardiovascular system or reproductive problems |
| BHC-GAMMA | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Carbofuran | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| HEXACHLOROBENZENE | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Nitrite | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Arsenic | Health-Based | N/A | 0.013 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0343 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0102 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.01325 | Jun 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| TTHM | Health-Based | N/A | 160 | Jun 30, 2021 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Health-Based | N/A | 100 | Jun 30, 2021 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.0348 | Jun 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.01023 | Jun 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Mar 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| TTHM | Health-Based | N/A | 100 | Mar 31, 2021 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Health-Based | N/A | 71.5 | Mar 31, 2021 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.0323 | Mar 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.01073 | Mar 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0215 | Mar 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Mar 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| 1,2-DIBROMO-3-CHLOROPROPANE | Health-Based | N/A | 0.000229 | Mar 31, 2021 | Resolved | N/A |
| 1,2-DIBROMO-3-CHLOROPROPANE | Health-Based | N/A | 0.000229 | Mar 31, 2021 | Resolved | N/A |